InflaRx to host conference call today at 8:30 am EDT / 2:30 pm CEST JENA, Germany, Oct. 27, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing ...
Interim results will be available by the end of 2021 with final results expected in 2022 Initial positive data from the first 5 patients previously announced in Q1 2020 JENA, Germany, April 15, 2021 ...
JENA, Deutschland - InflaRx N.V. (NASDAQ:IFRX) hat Post-hoc-Analysen veröffentlicht, die trotz des vorzeitigen Abbruchs der Phase-3-Studie potenzielle Wirksamkeitssignale für Vilobelimab bei Pyoderma ...
JENA, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ...
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers JENA, Germany, June 13, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative ...
Darin hatten 13 Patienten mit Pyoderma gangraenosum (Dermatitis ulcerosa) randomisiert und doppelblind eine einmalige Infusion mit 5 mg/kg des TNF-alpha-Blockers Infliximab (Remicade®) erhalten. 17 ...
Der Anruf kommt aus einer Aachener Klinik. Die Stimme am Telefon klingt schwach. Doch dann schwingt Freude mit übers Wiedererkennen und Erinnern an ihre Geschichte, die wir im vorigen Sommer in ...
Eine 33-jährige Frau stellte sich mit sehr schmerzhaften Hautveränderungen an ihrem Oberschenkel vor. An Vorerkrankungen bestand eine Colitis ulcerosa. Die Zuweisung erfolgte unter der ...
Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesion Treatment was well tolerated; no adverse events associated with ...
Target enrollment of 18 patients reached across three different dose groups Interim results will be available by the end of 2021 with final results expected in 2022 Initial positive data from the ...
Two out of the first five patients dosed with IFX-1 achieved complete remission Dose escalation warranted by pharmacodynamic analysis and approved by relevant authorities for a total enrollment of 18 ...
InflaRx to host conference call today at 8:30 am EDT / 2:30 pm CEST JENA, Germany, Oct. 27, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback